企業プロフィール
ImmuCell 株価・ニュース・カタリスト
- ティッカー:
- ICCC
- 取引所:
- NASDAQ
- セクター:
- Biopharma
- 所在地:
- United States
株価パフォーマンス
10.06 USD (-0.30%)
終値
最終更新: 2026年8月21日
88.6M USD
時価総額
株価変動の要因
As of Aug 21, 2026, ICCC closed down 0.30% at $10.06. No new same-company headline was identified in the current news window.
企業概要
Animal Health Biologics Company
ImmuCell develops biologic products intended to improve calf health and productivity. The company primarily serves dairy and livestock markets, with an emphasis on preventing early-life diseases such as neonatal calf diarrhea.
First Defense Franchise
The First Defense product line orally delivers antibodies derived from colostrum to provide immediate immune protection against major viral and bacterial causes of calf scours. Dual-Force and Tri-Shield are the franchise’s key growth products.
Commercial Execution
Growth depends on product availability, U.S. market demand, expansion of the commercial team, and distributor inventory cycles. The release did not identify a specific future clinical or regulatory milestone.
今後のカタリスト
- ImmuCell’s catalysts are animal-health product demand, manufacturing execution, and steady recurring revenue in veterinary biologics. The company moves on operating consistency rather than binary headlines.
最近のニュース
- 01
- 02
- 03
- 04
- 05
類似銘柄
事業成熟度、治療領域、カタリスト傾向が近い同業銘柄です。